Novocure logo

Novocure

NVCR | NASDAQ
Chart Builder DCF Calculator
$11.30
-$0.53 (-4.48%)
At close: Nov 16, 2026, 4:00 PM ET
$11.26
-$0.04 (-0.35%)
After-hours: Nov 16, 2026, 7:43 PM ET
-4.48%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
55.5
Fundamentals Strong
Market Sentiment Neutral
Moat Narrow
Sector Rank #181/1021 (Top 18%)

Key Statistics

Market Data

Market Cap $1.32B
1D Range
11.25 11.73
52W Range
10.03 19.99

Valuation (TTM)

PE -10.66
PB 3.77
EV/EBITDA -10.45

Valuation (NTM)

Forward PE N/A
Forward PEG 0.45
Price Target $26.00
Loading financial charts...

Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United...

Sector Healthcare
Employees 1,605
IPO Date Oct 2, 2015
Fiscal Year January - December

Latest News

JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer

3 days ago · businesswire.com

JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer
FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

6 days ago · fool.com

FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.
Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer

8 days ago · businesswire.com

Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer
Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock

15 days ago · zacks.com

Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock
NovoCure: 3 Key Takeaways for Long-Term Investors

15 days ago · fool.com

NovoCure: 3 Key Takeaways for Long-Term Investors
NovoCure Limited (NVCR) Q3 2026 Earnings Call Transcript

18 days ago · seekingalpha.com

NovoCure Limited (NVCR) Q3 2026 Earnings Call Transcript
NovoCure Q3 Earnings Call Highlights

18 days ago · marketbeat.com

NovoCure Q3 Earnings Call Highlights
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates

19 days ago · zacks.com

NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement

20 days ago · businesswire.com

Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
Novocure: A Mispriced Cash-Generating Biotech With Upside Potential

1 month ago · seekingalpha.com

Novocure: A Mispriced Cash-Generating Biotech With Upside Potential

Earnings

Latest Earnings
Oct 29, 2026
EPS
-$0.09
Beat +61.68%
REV
$193.4M
Beat +6.10%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
5
Consensus
Buy
Price Target
$26.00
Upside
+130.09%
Buy (3)
Hold (2)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.